Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.47 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | DHFR | P00374 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29213722 | 0.86 | TDP1 (0.64) | LMNAMAPTTDP1CYP1A2CYP3A4 | |
| SCHEMBL3267158 | 0.84 | TDP1 (0.51) | LMNACYP4F2CYP4A11TDP1L3MBTL1 | |
| SCHEMBL27921658 | 0.84 | LMNA (0.59) | LMNAMAPTTDP1L3MBTL1CYP1A2 | |
| SCHEMBL12610480 | 0.84 | CNR1 (0.47) | CYP4F2CYP4A11 | |
| SCHEMBL9469608 | 0.83 | NPC1 (0.49) | MAPTCYP4F2CYP4A11TDP1L3MBTL1 | |
| SCHEMBL9469479 | 0.83 | CYP4F2 (0.48) | CYP4F2CYP4A11TDP1L3MBTL1CYSLTR2 | |
| SCHEMBL2987183 | 0.83 | CYP1A2 (0.58) | CYP4F2CYP4A11TDP1L3MBTL1CYSLTR2 | |
| Methyl Salicylate SCHEMBL4573550 | 0.83 | LMNA (0.54) | LMNAGAAMAPTTDP1L3MBTL1 | |
| SCHEMBL3154126 | 0.82 | L3MBTL1 (0.62) | LMNAGAAMAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL2903656 | 0.82 | ALDH1A1 (0.57) | LMNAMAPTCYP4F2CYP4A11TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3546452-A1 | ANTIMALARIAL COMPOUNDS WITH FLEXIBLE SIDE-CHAINS | MMV Medicines for Malaria Venture (CH) | 2019-10-02 | — | — | EP | disclosed |
| EP-2194985-B1 | ANTIMALARIAL COMPOUNDS WITH FLEXIBLE SIDE-CHAINS | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2019-02-20 | — | — | EP | disclosed |
| US-8530491-B2 | Antimalarial compounds with flexible side-chains | MEDICINES FOR MALARIA VENTURE (MMV) (CH) | 2013-09-10 | — | — | US | disclosed |
| CN-101820879-B | Antimalarial compounds with flexible side-chains | MEDICINES MALARIA VENTURE MMV | 2013-01-02 | — | — | CN | disclosed |
| CN-101820879-A | Antimalarial compounds with flexible side-chains | MEDICINES MALARIA VENTURE MMV | 2010-09-01 | — | — | CN | disclosed |
| EP-2194985-A1 | ANTIMALARIAL COMPOUNDS WITH FLEXIBLE SIDE-CHAINS | Medicines for Malaria Venture (CH) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009048957-A1 | ANTIMALARIAL COMPOUNDS WITH FLEXIBLE SIDE-CHAINS | MEDICINES FOR MALARIA VENTURE (CH) | 2009-04-16 | — | — | WO | disclosed |
| US-20090099220-A1 | ANTIMALARIAL COMPOUNDS WITH FLEXIBLE SIDE-CHAINS | MEDICINES FOR MALARIA VENTURE | 2009-04-16 | — | — | US | disclosed |
| US-6046183-A | SYNERGISTIC MIXTURE OF FINASTERIDE AND DOXAZOSIN | MERCK & CO., INC. (US) | 2000-04-04 | — | — | US | disclosed |
| US-5994362-A | ADMINISTERING FINASTERIDE AND CASODEX | MERCK & CO., INC. (US) | 1999-11-30 | — | — | US | disclosed |
| US-5753641-A | SYNERGISTIC THERAPY COMPRISING FINASTERIDE AND TERAZOSIN DRUGS | MERCK & CO., INC. (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0576603-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC HYPERPLASIA, CONTAINING A 5 ALPHA-REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO. INC. (US) | 1994-01-05 | — | — | EP | disclosed |
| EP-0525888-A1 | New catechol type non-steroidal drugs as 5-alpha reductase inhibitors | MERCK & CO. INC. (US) | 1993-02-03 | — | — | EP | disclosed |
| WO-1992018132-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA COMTAINING A 5 ALPHA-REDUCTASE INHIBITOR | MERCK & CO., INC. (US) | 1992-10-29 | — | — | WO | disclosed |
| WO-1992016213-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC HYPERPLASIA, CONTAINING A 5 ALPHA-REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
| WO-1992016233-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC CANCER CONTAINING A 5 ALPHA REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099220-A1 | ANTIMALARIAL COMPOUNDS WITH FLEXIBLE SIDE-CHAINS | DHFR, FPGS, DHODH | JAK2 2409/4885LMNA 3658/4885GAA 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.